Mediterranean diet, active surveillance, and low-risk prostate cancer: the details

As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …

Mediterranean diet, active surveillance, and low-risk prostate cancer

The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …

FDA approves first gallium-68 PSMA PET scan imaging agent in US, BUT …

Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men  with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …

“Doctor, where did my cancer go?”

Some 18 months ago we had written about the possible occurrence of spontaneous remissions in men on active surveillance (AS) for low-risk forms of prostate cancer. We were therefore very interested in a recent article closely related to this topic. … READ MORE..

The epidemiology of prostate cancer (2003-2017)

A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …

AS for lower-risk forms of prostate cancer needs celebrity endorsement

The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …

The PSA test in “screening” for prostate cancer: yesterday, today, and tomorrow

So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …

Breakthrough Device Designation for miR Sentinel™ urine test

According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …

The virtual prostate cancer patient

A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …

Webinar 2 on “Active Surveillance & Beyond”

At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …

Adding ADT to external beam radiation only benefits unfavorable risk patients

In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …

Who actually dies from prostate cancer? Additional observations

Earlier today we reported on a recent publication based on data from the CaPSURE registry database, which stated that, among men enrolled in that database, men died sooner from their prostate cancer after they progressed to having metastatic disease over time (median survival, 2.4 years from onset of metastasis) than died from their prostate cancer if they were initially diagnosed with metastatic disease (median survival, 5.3 years). … READ MORE …

Who actually dies from prostate cancer?

Some readers are probably going to find this very hard to believe, but … according to a newly published study, men initially diagnosed with metastatic prostate cancer are actually less likely to die from their cancer than men who are initially diagnosed with non-metastatic disease but who progress to having metastatic disease over time. … READ MORE …

miR Sentinel tests 90+ percent accurate in diagnosis of prostate cancer

Earlier this year, at the annual Genitourinary Cancer symposium in San Francisco, we were first given information about the potential of three new tests for the diagnosis of prostate cancer: the so-called miR Sentinel tests from miR Scientific. … READ MORE …

Prostate cancer research: a landscape analysis

We have recently learned that Movember conducted a major landscape analysis of unmet research needs in prostate cancer that started back in 2017 and ran through 2019 but just got published in 2020. … READ MORE …